Research programme: postmyocardial infarction therapy - BioDiem

Alternative Names: BDM-K; Postmyocardial infarction therapy research programme - BioDiem

Latest Information Update: 13 Apr 2007

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Dec 2006 No development reported - Clinical-Phase-Unknown for Postmyocardial infarction in Russia (PO)
31 Dec 2006 No development reported - Preclinical for Postmyocardial infarction in Australia (PO)
28 Sep 2004 Clinical trials in Postmyocardial infarction in Russia (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com